Innate Pharma S.A.
IPHA · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $4,860 | $276 | $12,345 | $16,557 |
| % Growth | 1,660.9% | -97.8% | -25.4% | – |
| Cost of Goods Sold | $20,520 | -$29,076 | $29,076 | $24,569 |
| Gross Profit | -$15,660 | $29,352 | -$16,731 | -$3,126 |
| % Margin | -322.2% | 10,634.8% | -135.5% | -18.9% |
| R&D Expenses | $20,520 | $22,904 | $29,076 | $24,569 |
| G&A Expenses | $9,611 | $2,515 | $9,418 | $8,970 |
| SG&A Expenses | $9,767 | $2,351 | $9,582 | $9,144 |
| Sales & Mktg Exp. | $156 | -$164 | $164 | $174 |
| Other Operating Expenses | -$20,520 | $29,359 | -$29,076 | -$24,568 |
| Operating Expenses | $9,767 | $54,614 | $9,582 | $9,145 |
| Operating Income | -$25,427 | -$25,262 | -$26,313 | -$7,416 |
| % Margin | -523.2% | -9,152.9% | -213.1% | -44.8% |
| Other Income/Exp. Net | $4,083 | $555 | $1,549 | $2,982 |
| Pre-Tax Income | -$21,344 | -$24,707 | -$24,764 | -$4,434 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$21,344 | -$24,707 | -$24,764 | -$9,288 |
| % Margin | -439.2% | -8,951.8% | -200.6% | -56.1% |
| EPS | -0.25 | -0.3 | -0.31 | -0.12 |
| % Growth | 16.7% | 3.2% | -158.3% | – |
| EPS Diluted | -0.25 | -0.3 | -0.31 | -0.12 |
| Weighted Avg Shares Out | 85,376 | 81,052 | 79,884 | 80,587 |
| Weighted Avg Shares Out Dil | 86,937 | 81,052 | 80,872 | 80,587 |
| Supplemental Information | – | – | – | – |
| Interest Income | $564 | $101 | $2,538 | $11,938 |
| Interest Expense | $0 | $34 | $600 | $3,022 |
| Depreciation & Amortization | $366 | $1,244 | $750 | $1,874 |
| EBITDA | -$25,061 | -$21,348 | -$25,563 | -$10,396 |
| % Margin | -515.7% | -7,734.8% | -207.1% | -62.8% |